Zobrazeno 1 - 10
of 1 273
pro vyhledávání: '"Laurent PEYRIN-BIROULET"'
Autor:
Xiang Guo, Peter M Irving, Laurent Peyrin-Biroulet, Séverine Vermeire, Joseph Wu, Irene Modesto, David T Rubin, Marla C Dubinsky, Andres J Yarur, Miguel Regueiro, Martina Goetsch, Krisztina Lazin, Guibao Gu, Aoibhinn McDonnell, Jesse Green, Alexis B Dalam
Publikováno v:
BMJ Open Gastroenterology, Vol 12, Iss 1 (2025)
Objective Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). S1P1 receptor expression on cardiac cells is involved in cardiac c
Externí odkaz:
https://doaj.org/article/b212f7517123440db074ec0c6b1b17ac
Autor:
Sudheer K. Vuyyuru, Christopher Ma, Tran M. Nguyen, Guangyong Zou, Laurent Peyrin-Biroulet, Silvio Danese, Parambir Dulai, Neeraj Narula, Siddharth Singh, Vipul Jairath
Publikováno v:
EClinicalMedicine, Vol 78, Iss , Pp 102980- (2024)
Externí odkaz:
https://doaj.org/article/129ff5d12a054abe8a1ede95edcd9d75
Autor:
Fabrizio Fanizzi, Mariangela Allocca, Gionata Fiorino, Alessandra Zilli, Federica Furfaro, Tommaso Lorenzo Parigi, Laurent Peyrin-Biroulet, Silvio Danese, Ferdinando D’Amico
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by growing incidence and prevalence around the world in the last few decades. The range of available existing treatment and strategies for its management is being implement
Externí odkaz:
https://doaj.org/article/9996cfbd99d643b48ed8164be1b8763b
Autor:
Laurent Peyrin‐Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Marc Ferrante, Jordi Guardiola, Jørgen Jahnsen, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Philip J Smith, Taek Kwon, Jeeyoung Kim, Sangwook Yoon, Dong-Hyeon Kim, Raja Atreya
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background While indirect comparison of infliximab (IFX) and vedolizumab (VDZ) in adults with Crohn’s disease (CD) or ulcerative colitis (UC) shows that IFX has better effectiveness during induction, and comparable efficacy during maintena
Externí odkaz:
https://doaj.org/article/5d1ccaccfa3b4ae6bc5630baead360c9
Autor:
Lucia Centanni, Clelia Cicerone, Fabrizio Fanizzi, Ferdinando D’Amico, Federica Furfaro, Alessandra Zilli, Tommaso Lorenzo Parigi, Laurent Peyrin-Biroulet, Silvio Danese, Mariangela Allocca
Publikováno v:
Pharmaceuticals, Vol 18, Iss 1, p 78 (2025)
Inflammatory bowel diseases (IBD) including Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, relapsing conditions characterized by dysregulated immune responses and persistent intestinal inflammation. This review aims to examine new po
Externí odkaz:
https://doaj.org/article/86382e0680fd4a76a225e06e9c9e6c6a
Autor:
Francesca Bernardi, Fabrizio Fanizzi, Tommaso Lorenzo Parigi, Alessandra Zilli, Mariangela Allocca, Federica Furfaro, Laurent Peyrin-Biroulet, Silvio Danese, Ferdinando D’Amico
Publikováno v:
Microorganisms, Vol 13, Iss 1, p 19 (2024)
Acute severe ulcerative colitis (ASUC) often requires surgical intervention, such as proctocolectomy with ileal pouch–anal anastomosis (IPAA). While IPAA improves patient outcomes, it can be associated with pouchitis, a common and debilitating comp
Externí odkaz:
https://doaj.org/article/9fb464516e3b4552b237a8919a949cd3
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
Autor:
Bénédicte Caron, Philippe Seksik, Anthony Buisson, Pauline Wils, Guillaume Savoye, Carmen Stefanescu, David Laharie, Lucas Guillo, Vered Abitbol, Joelle Bonnet, Romain Altwegg, Lucine Vuitton, Driffa Moussata, Arnaud Bourreille, Amélie Biron, Cyrielle Gilletta, Mathurin Fumery, Stephane Nahon, Stephane Nancey, Houda Camara, Laurent Peyrin-Biroulet
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Background: Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown. Objectives: This study investigated IBD patient satisfaction with approved adalim
Externí odkaz:
https://doaj.org/article/7ca0c8a49c264203b43510c27bcad604
Publikováno v:
Arquivos de Gastroenterologia, Vol 61 (2024)
ABSTRACT Inflammatory bowel diseases (IBD) currently impose an immense social and economic burden on society in terms of both direct and indirect healthcare costs. Their incurable and progressive nature results in an unavoidable lifetime expense. The
Externí odkaz:
https://doaj.org/article/94a04c66f7924eee895c4f7e34c6439b
Autor:
Shaji Sebastian, Laurent Peyrin-Biroulet, Silvio Danese, Séverine Vermeire, Simon Travis, Jean-Frederic Colombel, Brian G Feagan, Vipul Jairath, Guangyong Zou, Geert R D’Haens, William J Sandborn, Gordon W Moran, Christopher Ma, Peter Bossuyt, Daniel Green, Mark S Silverberg, Maria Kłopocka, Marek Horynski, Stefanie C McFarlane, Zhongya Wang, Shashi Adsul, Marcelo Freire, Gabriela Radulescu, Julie Sigler, Jurij Hanžel, Rocio Sedano, Naveen Arya, Melanie Beaton, William Harlan, Rima Petroniene, Lukasz Wolanski
Publikováno v:
BMJ Open Gastroenterology, Vol 11, Iss 1 (2024)
Introduction Symptoms, endoscopy and histology have been proposed as therapeutic targets in ulcerative colitis (UC). Observational studies suggest that the achievement of histologic remission may be associated with a lower risk of complications, comp
Externí odkaz:
https://doaj.org/article/90b48a3e247b434da3279f2d6dcef059
Autor:
Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, Marc Ferrante, Satoshi Motoya, Remo Panaccione, Joana Torres, Ryan C. Ungaro, Kristina Kligys, Jasmina Kalabic, Javier Zambrano, Yafei Zhang, Geert D'Haens
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 4, Pp 539-550 (2024)
Background and Aims: Early biologic therapy treatment has demonstrated better outcomes in Crohn’s disease (CD). We evaluated the impact of CD duration in patients with moderately to severely active CD treated with risankizumab therapy. Methods: Thi
Externí odkaz:
https://doaj.org/article/fa55166e9c4e42f79099e540030db28a